Ursodeoxycholic Acid in C. Difficile Infection

• Status: Recruiting
• Trial end date: 2024-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nottingham University Hospitals NHS Trust
• Treatments: Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

• Completion of a course of antibiotic treatment for C. difficile infection within the previous 7 days

Exclusion Criteria:

• • Pregnant or Breast-feeding

• Gall bladder inflammation

• Frequent episodes of biliary colic

• Occlusion of the common bile duct or cystic duct

• Active small intestinal inflammation

• Previous resection of distal small intestine

• Treatment with bile salt binding agents, ciclosporin or ciprofloxacin

• Diarrhoea (from any cause) at study initiation

• hypersensitivity to bile acids or any excipient of the formulation

• Life expectancy less than 6 months